Pylarify injection
Ended Awarded Last action
- Contract number
- 36C24825N0147
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 8
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $1,335,226
Award facts
- Contract value 100% obligated
- $1,335,226.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$396,959 | |
| Original award | $1,732,186 |
About this award
Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., received a firm fixed-price blanket purchase agreement (BPA) call valued at $1.335 million from Veterans Integrated Service Network (VISN) 8 for PYLARIFY Injection, with a completion date of December 31, 2025. PYLARIFY (piflufolastat F-18) is a radiopharmaceutical diagnostic imaging agent used in positron emission tomography (PET) scans for the detection and localization of prostate cancer, supporting advanced oncology diagnostic capabilities across the VA healthcare system. This contract award operates under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) master contract vehicle and carries no set-aside designation, enabling VISN 8 to procure critical radiopharmaceutical supplies through an established indefinite delivery framework. Performance will occur at the contractor's manufacturing and distribution facility in North Billerica, Massachusetts.
This award represents a continuation of Progenics' substantial federal contracting relationship with the Department of Veterans Affairs, which has awarded the company over 150 individual contract orders across multiple Veterans Integrated Service Networks, the Defense Health Agency, and the National Institutes of Health. The parent company, Lantheus Holdings, Inc., maintains a significant $290 million Federal Supply Schedule contract with VISN 12 extending through March 2030, establishing the organization as a primary supplier of radiopharmaceutical products across the federal healthcare system. Awards to Progenics have historically ranged from approximately $10,000 to over $9 million, with firm fixed-price structures ensuring cost certainty for government medical imaging programs supporting prostate cancer diagnostic initiatives.
Quick answers
Who was awarded contract 36C24825N0147?
36C24825N0147 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 8 (Veterans Health Administration) on January 1, 2025.
How much is contract 36C24825N0147 worth?
The government has obligated $1,335,226 on 36C24825N0147.
Is contract 36C24825N0147 an order under another contract?
Yes. 36C24825N0147 is a BPA call under 36F79719D0170-36C24823A0018, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24825N0147 competed?
The extent of competition for 36C24825N0147 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award